Company Overview of Resolve Therapeutics, LLC
Resolve Therapeutics, LLC is a clinical stage biopharmaceutical company that develops biologic products for the treatment of autoimmune diseases, including systemic lupus erythematosus and Sjögrens syndrome. Its products include RSLV-132, a mono-specific nuclease Fc-fusion protein that targets and destroys immune complexes to prevent the activation of interferon and ameliorate the kidney damage caused by the immune complexes; and RSLV-133, a bi-specific Fc-nuclease fusion protein that is engineered to incorporate two different nuclease activities into one drug molecule. The company was founded in 2010 and is based in Seattle, Washington.
454 North 34th Street
Seattle, WA 98103
Founded in 2010
Key Executives for Resolve Therapeutics, LLC
Co-Founder and Chief Executive Officer
Compensation as of Fiscal Year 2016.
Resolve Therapeutics, LLC Key Developments
Resolve Therapeutics, LLC Announces Positive Clinical Data from RSLV-132 Lupus Study
Feb 10 16
Resolve Therapeutics, LLC announced the successful completion of a multiple ascending dose study in patients with systemic lupus erythematosus (SLE) with its lead compound RSLV-132. Data from a multicenter phase double-blind, placebo-controlled multiple ascending dose study of RSLV-132 in 32 subjects with SLE demonstrate the safety and tolerability of the compound. The study investigated three to five doses of RSLV-132 in four dose cohorts ranging from 0.3 mg/kg to 10 mg/kg given either weekly or bi-weekly in patients with mild SLE. The frequency of adverse events (AEs) was similar between the placebo and drug-treated groups, with the majority of AEs being mild and not related to the dose of RSLV-132. There were no deaths in the study and only one discontinuation due to a severe adverse event (SAE) which was not drug related. The serum half-life of RSLV-132 was approximately 19 days, potentially supporting monthly dosing. Additionally, there were no subjects in the study that tested positive for anti-RSLV-132 antibodies. While the study was conducted in subjects with primarily mild or inactive disease, changes in disease activity were monitored throughout the study using the systemic lupus erythematosus disease activity index (SLEDAI). Of the evaluable subjects with a SLEDAI >0 (N=22), a greater proportion of RSLV-132 treated subjects (44%) had an improvement in disease activity as compared to placebo treated subjects (33%). SLEDAI improvements in the RSLV-132 treated subjects were accompanied in some cases by decreases in RNA autoantibodies or interferon signature. SLE is an autoimmune disease affecting an estimated 400,000 patients in the Unites States and up to 5 million worldwide, 90% of whom are women. The standard of care in lupus has not significantly improved in over forty years and relies on steroids and potent immunosuppressive agents with limited effectiveness and serious side effects. Effective, safe therapy for SLE is urgently needed to address the unmet medical need. A large and growing body of scientific data point to the central role of RNA bound to autoantibody immune complexes in the activation of the interferon pathway. RSLV-132 is a novel Fc fusion protein consisting of human RNase attached to the Fc portion of human IgG which is designed to enzymatically digest the RNA contained in immune complexes thereby preventing the chronic activation of interferon and inflammation characteristic of SLE.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries